v3.25.4
Segment financial information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of segment financial information
The following tables present information by reportable segment:    
(in millions)
Net sales
Year ended December 31,
Adjusted Operating Income
Year ended December 31,
202520242023202520242023
Laboratory Solutions$4,399.7 $4,610.1 $4,738.3 $510.4 $598.0 $668.3 
Bioscience Production2,152.5 2,173.5 2,228.9 517.8 558.2 601.9 
Corporate— — — (70.4)(66.4)(58.4)
Total$6,552.2 $6,783.6 $6,967.2 $957.8 $1,089.8 $1,211.8 
(in millions)
Year ended December 31, 2025Laboratory SolutionsBioscience ProductionCorporateTotal
Net sales$4,399.7 $2,152.5 $— $6,552.2 
Adjusted cost of sales1
3,210.5 1,201.9 (0.2)4,412.2 
Adjusted operating expenses2
678.8 432.8 70.6 1,182.2 
Adjusted Operating Income$510.4 $517.8 $(70.4)$957.8 
(in millions)
Year ended December 31, 2024Laboratory SolutionsBioscience ProductionCorporateTotal
Net sales$4,610.1 $2,173.5 $— $6,783.6 
Adjusted cost of sales1
3,288.4 1,203.8 — 4,492.2 
Adjusted operating expenses2
723.7 411.5 66.4 1,201.6 
Adjusted Operating Income$598.0 $558.2 $(66.4)$1,089.8 
(in millions)
Year ended December 31, 2023Laboratory SolutionsBioscience ProductionCorporateTotal
Net sales$4,738.3 $2,228.9 $— $6,967.2 
Adjusted cost of sales1
3,380.3 1,223.1 — 4,603.4 
Adjusted operating expenses2
689.7 403.9 58.4 1,152.0 
Adjusted Operating Income$668.3 $601.9 $(58.4)$1,211.8 
━━━━━━━━━
1.Adjusted cost of sales excludes $0.6 million and $12.1 million of non-GAAP adjustments for the years ended December 31, 2025 and December 31, 2024, respectively, primarily related to restructuring and severance as described in more detail within the non-GAAP reconciliation presented below. There were no such non-GAAP adjustments to cost of sales for the year ended December 31, 2023.
2.Adjusted operating expenses excludes $1,203.4 million, $(7.1) million and $515.4 million of non-GAAP adjustments, for the years ended December 31, 2025, December 31, 2024 and December 31, 2023, respectively, primarily related to gain on sale of business, amortization, impairment charges, restructuring and severance charges and transformation expenses as described in more detail within the non-GAAP reconciliation presented below.
The following table presents depreciation and amortization by reportable segment:
(in millions)
Depreciation and amortization
Year ended December 31,
202520242023
Laboratory Solutions$205.8 $212.8 $215.0 
Bioscience Production204.4 192.7 187.3 
Total$410.2 $405.5 $402.3 
Information about our segments’ assets and capital expenditures is not disclosed because this information is not provided to our CODM.
Reconciliation of segment profitability from consolidated earnings
The following table presents the reconciliation of Adjusted Operating Income, our segment profitability measure, to (Loss) income before income taxes, the nearest measurement under GAAP:
(in millions)
Year ended December 31,
202520242023
Adjusted Operating Income$957.8 $1,089.8 $1,211.8 
Amortization(301.1)(299.8)(307.7)
Integration-related expenses1
— — (7.6)
Restructuring and severance charges2
(29.8)(82.8)(26.5)
Transformation expenses3
(61.7)(58.9)(5.4)
Reserve for certain legal matters, net4
(7.3)(9.2)(7.1)
Other5
(14.0)(0.9)(0.3)
Impairment charges6
(785.0)— (160.8)
Gain on sale of business7
(5.1)446.6 — 
Interest expense, net(169.8)(218.8)(284.8)
Loss on extinguishment of debt(4.6)(10.9)(6.9)
Other (expense) income, net
(20.7)(1.2)5.8 
(Loss) income before income taxes
$(441.3)$853.9 $410.5 
━━━━━━━━━
1.Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to
normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
2.Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. These expenses recognized in 2024 & 2025 represent costs incurred to achieve the Company’s publicly-announced cost transformation initiative.
3.Represents incremental expenses directly associated with the Company’s publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
4.Represents charges and legal costs, net of recoveries, in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
5.Represents other stock-based compensation expense (benefit), $6.7 million of severance and transition costs associated with the replacement of our Chief Executive Officer in 2025, and other costs.
6.As described in notes 10 and 11.
7.The amount reported in 2024 reflects the gain on the sale of our Clinical Services business. The amount reported in 2025 reflects post‑closing purchase price adjustments related to that sale. The sale of the Clinical Services business is further described in note 4.
Schedule of net sales by product line
The following table presents net sales by product category:
(in millions)
Year ended December 31,
202520242023
Proprietary$3,448.9 $3,615.1 $3,720.2 
Third-party3,103.3 3,168.5 3,247.0 
Total$6,552.2 $6,783.6 $6,967.2 
Schedule of information by geographic area
The following table presents information by geographic area:
(in millions)
Net sales
Year ended December 31,
Property, plant and equipment, net
Year ended December 31,
20252024202320252024
United States$3,279.7 $3,549.6 $3,705.2 $470.4 $445.8 
All other countries3,272.5 3,234.0 3,262.0 296.4 262.3 
Total$6,552.2 $6,783.6 $6,967.2 $766.8 $708.1